Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
9.66
+0.33 (3.54%)
Nov 21, 2024, 1:24 PM EST - Market open
Immunome Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| Revenue | 10.13 | 14.02 | - | - | - | - | Upgrade
|
| Cost of Revenue | 91.13 | 22.93 | 23.11 | - | - | - | Upgrade
|
| Gross Profit | -81 | -8.91 | -23.11 | - | - | - | Upgrade
|
| Selling, General & Admin | 30.71 | 19.82 | 13.79 | 11.09 | 4.78 | 1.53 | Upgrade
|
| Research & Development | - | - | - | 14.11 | 7.49 | 8.82 | Upgrade
|
| Operating Expenses | 30.71 | 19.82 | 13.79 | 25.2 | 12.26 | 10.35 | Upgrade
|
| Operating Income | -111.71 | -28.73 | -36.9 | -25.2 | -12.26 | -10.35 | Upgrade
|
| Interest Expense | - | - | - | -0.01 | -0.04 | -0.11 | Upgrade
|
| Interest & Investment Income | 12.14 | 2.72 | 0.01 | - | - | 0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | - | -5.54 | - | Upgrade
|
| EBT Excluding Unusual Items | -99.57 | -26 | -36.9 | -25.21 | -17.84 | -10.44 | Upgrade
|
| Other Unusual Items | - | - | - | 0.5 | - | - | Upgrade
|
| Pretax Income | -305.35 | -106.81 | -36.9 | -24.71 | -17.84 | -10.44 | Upgrade
|
| Net Income | -305.35 | -106.81 | -36.9 | -24.71 | -17.84 | -10.44 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | 0.62 | - | - | - | Upgrade
|
| Net Income to Common | -305.35 | -106.81 | -37.52 | -24.71 | -17.84 | -10.44 | Upgrade
|
| Shares Outstanding (Basic) | 54 | 20 | 12 | 12 | 3 | 1 | Upgrade
|
| Shares Outstanding (Diluted) | 54 | 20 | 12 | 12 | 3 | 1 | Upgrade
|
| Shares Change (YoY) | 340.37% | 63.64% | 5.10% | 240.41% | 209.85% | 0.66% | Upgrade
|
| EPS (Basic) | -5.69 | -5.38 | -3.09 | -2.14 | -5.26 | -9.55 | Upgrade
|
| EPS (Diluted) | -5.69 | -5.38 | -3.09 | -2.14 | -5.26 | -9.55 | Upgrade
|
| Free Cash Flow | -138.68 | -8.4 | -28.94 | -18.31 | -12.72 | -9.83 | Upgrade
|
| Free Cash Flow Per Share | -2.59 | -0.42 | -2.39 | -1.59 | -3.75 | -8.99 | Upgrade
|
| Gross Margin | - | -63.54% | - | - | - | - | Upgrade
|
| Operating Margin | -1102.86% | -204.94% | - | - | - | - | Upgrade
|
| Profit Margin | -3014.59% | -761.92% | - | - | - | - | Upgrade
|
| Free Cash Flow Margin | -1369.09% | -59.92% | - | - | - | - | Upgrade
|
| EBITDA | -110.44 | -28.27 | -36.48 | -24.45 | -11.51 | -9.73 | Upgrade
|
| EBITDA Margin | - | -201.68% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 1.27 | 0.46 | 0.42 | 0.76 | 0.76 | 0.62 | Upgrade
|
| EBIT | -111.71 | -28.73 | -36.9 | -25.2 | -12.26 | -10.35 | Upgrade
|
| EBIT Margin | - | -204.94% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.